India's weight-loss drug market has hit a significant milestone of ₹2,000 crore, but recent data indicates that the explosive growth seen in the past year is stalling. Following the introduction of affordable versions of Ozempic (semaglutide) and Mounjaro (tirzepatide), sales surged initially, with semaglutide injections rising from 25,000 units in February to 1.9 lakh in May. However, growth momentum has slowed, raising questions about whether the influx of cheaper drugs genuinely expanded the patient base or merely shifted existing patients to more affordable options. While the market saw a plateau, innovator brands continue to demonstrate robust growth, with a 27% month-on-month increase, highlighting the ongoing confidence of healthcare providers in evidence-based therapies. Experts suggest that the market is transitioning to a more mature phase, focusing on long-term patient adherence and broader metabolic strategies, as India grapples with high obesity and diabetes rates. The future of the market will depend on balancing access with patient selection and medical supervision.